MDxHealth SA MDXH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDXH is a good fit for your portfolio.
News
-
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
-
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
-
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
-
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
-
ADRs Close Higher, Mobilicom Ltd. Climbs 41.4%
Trading Information
- Previous Close Price
- $2.50
- Day Range
- $2.52–2.71
- 52-Week Range
- $0.35–4.64
- Bid/Ask
- $2.57 / $2.98
- Market Cap
- $72.86 Mil
- Volume/Avg
- 700 / 71,424
Key Statistics
- Price/Earnings (Normalized)
- 3.51
- Price/Sales
- 0.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 236
- Website
- https://www.mdxhealth.com
Comparables
Valuation
|
Metric
|
MDXH
|
TIHE
|
VCYT
|
|---|---|---|---|
Price/Earnings (Normalized) | 3.51 | — | 26.68 |
Price/Book Value | — | — | 1.41 |
Price/Sales | 0.99 | — | 4.05 |
Price/Cash Flow | — | — | 30.22 |
Price/Earnings
MDXH
TIHE
VCYT
Financial Strength
|
Metric
|
MDXH
|
TIHE
|
VCYT
|
|---|---|---|---|
Quick Ratio | 2.19 | — | 4.19 |
Current Ratio | 2.42 | — | 4.66 |
Interest Coverage | −3.00 | — | −5,596.07 |
Quick Ratio
MDXH
TIHE
VCYT
Profitability
|
Metric
|
MDXH
|
TIHE
|
VCYT
|
|---|---|---|---|
Return on Assets (Normalized) | −31.26% | — | 7.85% |
Return on Equity (Normalized) | −380.84% | — | 8.41% |
Return on Invested Capital (Normalized) | −53.88% | — | 7.64% |
Return on Assets
MDXH
TIHE
VCYT
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Ntdchvwgfv | Grws | $219.5 Bil | |
DHR
| Danaher Corp | Kbqyslstl | Syglckm | $182.9 Bil | |
IQV
| IQVIA Holdings Inc | Ygpprbvn | Wrbsgxq | $42.4 Bil | |
A
| Agilent Technologies Inc | Cfmbgpnfcd | Zkxz | $40.6 Bil | |
IDXX
| IDEXX Laboratories Inc | Pfmpqdnvtt | Gvzfcg | $38.7 Bil | |
MTD
| Mettler-Toledo International Inc | Nxlmrzpjv | Hrqzz | $26.7 Bil | |
ICLR
| Icon PLC | Gvlfcfwbf | Bkbbgjq | $24.9 Bil | |
ILMN
| Illumina Inc | Ljqzqdgl | Pybnxbm | $19.9 Bil | |
WAT
| Waters Corp | Gnsrbnpkym | Ymftb | $18.7 Bil | |
LH
| Laboratory Corp of America Holdings | Hlfsstkdlt | Pbslft | $17.0 Bil |